Insider Selling: PTC Therapeutics (NASDAQ:PTCT) VP Sells $209,760.12 in Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Mark Elliott Boulding sold 3,019 shares of PTC Therapeutics stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $69.48, for a total value of $209,760.12. Following the transaction, the vice president directly owned 105,212 shares in the company, valued at $7,310,129.76. The trade was a 2.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Mark Elliott Boulding also recently made the following trade(s):

• On Wednesday, February 18th, Mark Elliott Boulding sold 3,081 shares of PTC Therapeutics stock. The shares were sold at an average price of $69.36, for a total value of $213,698.16.
• On Tuesday, February 17th, Mark Elliott Boulding sold 2,813 shares of PTC Therapeutics stock. The shares were sold at an average price of $69.29, for a total transaction of $194,912.77.
• On Friday, January 9th, Mark Elliott Boulding sold 2,314 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.93, for a total transaction of $180,330.02.
• On Thursday, January 8th, Mark Elliott Boulding sold 4,033 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.56, for a total transaction of $308,766.48.
• On Tuesday, January 6th, Mark Elliott Boulding sold 1,739 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.95, for a total transaction of $133,816.05.
• On Wednesday, January 7th, Mark Elliott Boulding sold 4,879 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.44, for a total value of $377,829.76.
• On Monday, January 5th, Mark Elliott Boulding sold 2,266 shares of PTC Therapeutics stock. The shares were sold at an average price of $75.55, for a total value of $171,196.30.

PTC Therapeutics Price Performance

Shares of PTC Therapeutics stock traded down $0.16 during trading on Monday, reaching $70.50. 1,444,030 shares of the company traded hands, compared to its average volume of 1,295,067. The firm has a market capitalization of $5.84 billion, a PE ratio of 9.11 and a beta of 0.48. PTC Therapeutics, Inc. has a 1-year low of $35.95 and a 1-year high of $87.50. The company has a 50 day moving average price of $74.91 and a 200-day moving average price of $68.14.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($1.46). The company had revenue of $164.68 million for the quarter, compared to analyst estimates of $281.45 million. PTC Therapeutics had a net margin of 39.44% and a negative return on equity of 362.45%. PTC Therapeutics’s revenue for the quarter was down 22.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.85) EPS. Equities research analysts expect that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Analysts Set New Price Targets

PTCT has been the subject of several recent research reports. Wells Fargo & Company decreased their price objective on PTC Therapeutics from $93.00 to $86.00 and set an “overweight” rating for the company in a report on Friday. Jefferies Financial Group lifted their price target on shares of PTC Therapeutics from $63.00 to $77.00 and gave the company a “buy” rating in a research report on Tuesday, October 28th. Morgan Stanley upped their price objective on shares of PTC Therapeutics from $90.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday. Wall Street Zen lowered shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, The Goldman Sachs Group boosted their target price on shares of PTC Therapeutics from $44.00 to $50.00 and gave the stock a “sell” rating in a research report on Wednesday, November 5th. Ten research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, PTC Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $80.93.

PTC Therapeutics News Roundup

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Cantor Fitzgerald reaffirmed a Buy rating on PTCT, which supports analyst confidence and can be a constructive signal for investors. Cantor Fitzgerald Sticks to Their Buy Rating for PTC Therapeutics (PTCT)
• Positive Sentiment: Management will present at upcoming investor conferences (including TD Cowen on March 2), offering an opportunity for management to update investors on commercial performance and pipeline progress. PTC Therapeutics to Participate at Upcoming Investor Conferences
• Neutral Sentiment: VP Mark Elliott Boulding disclosed a sale of 3,019 shares (~$209.8K) on Feb. 19; insider sales can be routine but add to recent selling activity that investors watch. Mark Elliott Boulding sale filing
• Negative Sentiment: CEO Matthew Klein sold 7,371 shares for ~$511k on Feb. 18 — a sizable insider sale by the CEO that may be viewed negatively by the market. Matthew Klein insider sale
• Negative Sentiment: Multiple other insiders (several VPs and directors) reported recent modest-to-mid-size sales in the same period, amplifying downward pressure as investors interpret clustered selling as a negative signal. Multiple insider sales reported

Institutional Investors Weigh In On PTC Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of PTC Therapeutics by 6.2% during the 4th quarter. Vanguard Group Inc. now owns 8,803,203 shares of the biopharmaceutical company’s stock worth $668,691,000 after buying an additional 514,204 shares in the last quarter. Wellington Management Group LLP increased its position in shares of PTC Therapeutics by 4.8% during the third quarter. Wellington Management Group LLP now owns 4,918,619 shares of the biopharmaceutical company’s stock valued at $301,856,000 after acquiring an additional 224,481 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in PTC Therapeutics by 28.6% during the fourth quarter. Janus Henderson Group PLC now owns 4,851,332 shares of the biopharmaceutical company’s stock worth $368,587,000 after acquiring an additional 1,077,776 shares during the period. State Street Corp lifted its holdings in PTC Therapeutics by 34.2% during the fourth quarter. State Street Corp now owns 4,206,126 shares of the biopharmaceutical company’s stock worth $319,497,000 after acquiring an additional 1,071,343 shares during the period. Finally, Toronto Dominion Bank boosted its position in PTC Therapeutics by 27.5% in the fourth quarter. Toronto Dominion Bank now owns 4,138,215 shares of the biopharmaceutical company’s stock worth $314,339,000 after purchasing an additional 891,690 shares during the last quarter.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.